Disclaimer: On July 2, 2024 the FDA approved Kisunla (donanemab-azbt) injection for the treatment of ... read more ↘ Alzheimer’s disease. Treatment should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials. ↖ read less
